Zeta CD103 Antibody. Zeta’s rabbit recombinant antibody recognizes CD103, a 150kDa integrin protein belonging to a small beta-7 integrin subfamily. CD103 is overexpressed in T-cell lymphomas and hairy cell leukemia (HCL). CD103 is a useful marker in an IHC panel for diagnosing HCL.
CD103 is the alpha-E integrin subunit of the heterodimeric alpha-E beta-7 (aEb7) integrin belonging to a small beta-7 integrin subfamily and is expressed by several cell types of the immune system and is involved in cell to cell or cell to matrix interactions. CD103 mediates cell adhesion, migration and lymphocyte homing through interaction with E-cadherin, which is expressed in epithelial cells.
CD103 is expressed on more than 95% of intraepithelial CD8+ cells and 40% of mucosa-associated T cells, whereas less than 2% of resting blood lymphocytes are CD103-positive. In several malignant conditions, such as T-cell lymphomas and hairy cell leukemia (HCL), the cells express CD103. Zeta’s antibody to CD103 is an extremely useful addition to the IHC panel for diagnosing hairy cell leukemia (HCL). Additionally, high CD103+ tumor infiltrating lymphocyte cell count is a favorable prognostic marker in a multitude of solid tumors, and high CD8+, CD103+ tissue resident memory T cells (TRM) are associated with metastasis and poorer clinical outcome in cutaneous squamous cell carcinoma.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.